A renewed debate has surfaced around the FDA’s Commissioner’s National Priority Review Voucher (CNPV) pilot, with experts urging a pause or reconsideration of the program’s details. Stakeholders say the framework still lacks clarity around candidate selection and the degree of senior-leader interference. The report cites healthcare consulting partner Michael Abrams and former FDA official Peter Pitts, who argued the voucher system is redundant to existing expedited pathways and should not override the agency’s internal review processes. The CNPV program, launched by former Commissioner Marty Makary last year, is intended to streamline review for products tied to U.S. national priorities and unmet needs. For drug developers, uncertainty around voucher allocation and governance can directly affect development timelines and portfolio strategy as the FDA continues to deploy accelerated review tools.